J L Grem
Overview
Explore the profile of J L Grem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Belongia E, Costa J, Gareen I, Grem J, Inadomi J, Kern E, et al.
NIH Consens State Sci Statements
. 2008 Oct;
25(2):1-29.
PMID: 18949020
Objective: To provide health care providers, patients, and the general public with a responsible assessment of currently available data on the management of hepatitis B. Participants: A non-DHHS, nonadvocate 12-member...
2.
Lehky T, Leonard G, Wilson R, Grem J, Floeter M
Muscle Nerve
. 2004 Feb;
29(3):387-92.
PMID: 14981738
Oxaliplatin, a platinum-based chemotherapeutic agent, is effective in the treatment of solid tumors, particularly colorectal cancer. During and immediately following oxaliplatin infusion, patients may experience cold-induced paresthesias, throat and jaw...
3.
Wright M, Schuler B, Szabo E, Grem J
Ann Oncol
. 2003 Mar;
14(4):659-60.
PMID: 12649120
No abstract available.
4.
Grem J, Yee L, Schuler B, HAMILTON J, Chen A, Chabuk C, et al.
Ann Oncol
. 2002 Feb;
12(11):1581-7.
PMID: 11822758
Background: We have reported that N-(phosphonacetyl)-L-aspartic acid (PALA) 1266 mg/m2 can safely be given 24 hours prior to the start of a 72-hour infusion of fluorouracil (FUra) and leucovorin (LV)...
5.
Ismail A, Grem J
Cancer Chemother Biol Response Modif
. 2001 Nov;
19:1-19.
PMID: 11686010
No abstract available.
6.
Thomas R, Dahut W, Harold N, Grem J, Monahan B, Liang M, et al.
Cancer Chemother Pharmacol
. 2001 Oct;
48(3):215-22.
PMID: 11592343
Purpose: To define the toxicity profile and the recommended phase II doses of 9-aminocamptothecin (9-AC) administered as a weekly 120-h infusion. Methods: 9-AC was administered over 120 h weekly to...
7.
Saif M, Wilson R, Harold N, Keith B, Dougherty D, Grem J
Anticancer Drugs
. 2001 Jul;
12(6):525-31.
PMID: 11459999
5-Fluorouracil (5-FU)-associated neurotoxicity is uncommon; symptoms may occur abruptly or more gradually during the course of chemotherapy. Peripheral neuropathy with 5-FU therapy has only rarely been reported. Two patients treated...
8.
Agnew E, Wilson R, Grem J, Neckers L, Bi D, Takimoto C
J Chromatogr B Biomed Sci Appl
. 2001 Jun;
755(1-2):237-43.
PMID: 11393709
A sensitive HPLC assay has been developed to determine the concentration of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in human plasma over the concentration range of 12.5 to 2,500 nM (7.33 to 1,465 ng/mL)....
9.
Guemei A, Cottrell J, Band R, Hehman H, Prudhomme M, Pavlov M, et al.
Cancer Chemother Pharmacol
. 2001 May;
47(4):283-90.
PMID: 11345644
Purpose: To characterize the relationships between human plasma irinotecan carboxylesterase-converting enzyme activity, caboxylesterase-mediated hydrolysis of p-nitrophenyl acetate (pNPA), and the butyrylcholinesterase-mediated hydrolysis of butyrylthiocholine in human plasma and to test...
10.
Grem J, Danenberg K, Behan K, Parr A, Young L, Danenberg P, et al.
Clin Cancer Res
. 2001 Apr;
7(4):999-1009.
PMID: 11309351
Purpose: To determine the expression of three targets of 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) in human tumor cell lines and to compare these with the 50% growth inhibition concentrations (GI(50))...